BIOWISDOM
APPOINTS INDUSTRY VETERAN AS DIRECTOR OF SALES AND BUSINESS DEVELOPMENT
FOR
RELEASE: 10th April 2003 Leading
provider of Drug Discovery Ontologies BioWisdom Ltd has announced that
Oliver Bayliss has been appointed as Director of Sales and Business
Development.
Bayliss
will spearhead the expansion of BioWisdom’s worldwide direct sales
operation using experience gained in his positions at Viaken Systems,
Accelrys, GCG, Oxford Molecular and DNAStar.
He will also develop and manage BioWisdom’s channel strategies,
working with a variety of scientific application and content providers to
deliver BioWisdom’s ontologies through a range of third party tools.
“BioWisdom
is providing its customers with very high quality, expertly annotated
ontologies focussed on drug discovery.
These ontologies underpin a number of critical R&D functions,
including effective searching, integration and navigation through the
complex research information pool.
These tools empower both expert informaticians and end-users
alike,” said Bayliss.
“I am very excited about joining the BioWisdom senior executive
team and look forward to helping the company continue the strong growth of
new pharmaceutical and biotech customers.”
“This
is a very timely appointment in BioWisdom’s development.
Our Discovery Ontologies are being deployed more widely in both
Europe and the US.
Oliver has over ten years international experience in sales and
business development for life science informatics companies,” said Dr
Gordon Smith Baxter, CEO of BioWisdom.
“He has a breadth of commercial skills, having successfully built
sales teams and developed new markets for a number of discovery solution
providers.”
About
BioWisdom
BioWisdom
Ltd., headquartered in Cambridge UK, established in September 2000, is a
biomedical informatics company developing systems which help R&D
professionals to access critical information and to assist them in the
discovery and development of novel drug therapies.
BioWisdom produces powerful life science ontologies, which describe
important discovery concepts such as targets (e.g. genes and proteins)
tissues and disease and the inter-relationships between them.
BioWisdom’s Discovery Ontologies deliver improved searching,
integration and navigation through complex research information.
-ENDS-
For
further information, please contact:
Gordon
Smith Baxter, CEO
BioWisdom
Ltd
Tel:
+44 (0)1223 492100
email:
gordon.baxter@biowisdom.com
http://www.biowisdom.com
